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Abstract Long-term high-level in vivo gene expression appears 
to depend on the promoter chosen to drive the gene of choice. In 
many cases the promoter appears to 'switch off some time after 
in vivo gene transfer. We demonstrate that, following intramus-
cular injection of ß-galactosidase reporter plasmids, promoter 
'switch off is due to elimination of fibres expressing the 
transferred reporter gene by activation of a Thl (cytotoxic) 
immune response. This finding, in the absence of stimulation of 
the immune system by viral vector proteins, has implications not 
only for gene transfer experiments but for the future of muscle-
directed gene therapy. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Skeletal muscle is an excellent target for in vivo gene trans-
fer. Once genetic material is introduced into muscle fibres it 
can remain there for very many months and may last for life 
(e.g. mouse studies [1]). This longevity of expression is prob-
ably due to the multinucleate post-mitotic nature of differen-
tiated skeletal muscle and reflects the stability of these struc-
tures. Consequently, skeletal muscle has been considered to 
serve as a useful platform for systemic expression of gene 
products in the treatment of non-muscle diseases, as well as 
being the target for direct genetic treatment of diseases such as 
Duchenne muscular dystrophy. Such gene therapies will re-
quire promoters that drive high-level expression in muscle. 
Viral promoters produce much higher levels of expression 
than eukaryotic promoters and one of the most widely used 
promoter constructs is derived from the cytomegalovirus 
(CMV) intermediate early promoter and enhancer. It has 
been reported that this promoter appears to decline in activity 
over time [2,3]. We examined the activity of this C M V pro-
moter and the Rous sarcoma virus (RSV) promoter in normal 
and immunocompromised animals to determine if this decline 
in expression was a property of the promoter or an in vivo 
response to foreign gene expression. 
*Corresponding author. Fax: (44) (181) 846-7377. 
2. Materials and methods 
2.1. Plasmid production 
The following three plasmids were used in the experiment: pCMV-
ß, which utilises the CMV intermediate early promoter and enhancer 
to drive the bacterial ß-galactosidase reporter gene (Clontech, Palo 
Alto, CA, USA); pRSV-ß, which utilises the RSV intermediate early 
promoter to drive the bacterial ß-galactosidase reporter gene [4]; 
pCMV-0, which was made from pCMV-ß by removing the ß-galacto-
sidase reporter gene with a Noil digest and religating the plasmid 
backbone. Plasmids were grown in JM109 E. coli and purified using 
Qiagen columns (Diagen) following the supplier's protocol with the 
following exception: after the final clearing spin, but before applica-
tion to the column, the lysate was incubated on ice for 5 min with 
Triton X-114 (final concentration 1%) to reduce endotoxin contami-
nants [5]. This step typically reduces endotoxin levels to less than 0.5 
IU/ug of plasmid, as assessed using the Limulus amoebocyte lysate 
assay (Etoxate, Sigma). The cleared treated lysate was then applied to 
the column and rinsed with 1.5 times the manufacturer's recom-
mended wash buffer volume. The rest of the procedure followed the 
manufacturer's instructions. Both restriction enzyme-cut and uncut 
plasmids were checked by agarose gel electrophoresis to confirm iden-
tity. This analysis demonstrated the absence of detectable contamina-
tion with RNA and that the majority (90%) of each plasmid was 
present as covalently closed circles. 
2.2. Injection of plasmid DNA in vivo 
BALB/c and nude BALB/c male mice were obtained from Harlan 
Olac, UK. They were reared in a minimal disease environment with 
food and water available ad libitum. Seven-week-old mice were in-
jected percutaneously with 25 ul of a 1.2% solution of barium chloride 
in normal saline, using a 27 gauge needle, into the middle of both 
anterior tibial muscles under Hypnorm-Hypnovel general anaesthesia 
[6]. Five days later, 25 u.g of plasmid DNA in normal saline at 1 ug/ul 
was similarly injected into the middle of each pre-treated muscle, 
again under general anaesthesia. Blood samples were taken by tail 
bleeding prior to injection of plasmid and at weekly intervals there-
after up to 6 weeks post injection of plasmid DNA. Pre-treatment 
with barium chloride was used to induce muscle regeneration as 
such regeneration has previously been shown to dramatically enhance 
gene expression following plasmid DNA gene transfer [7-10]. Barium 
chloride is a particularly effective myotoxic agent in mice giving re-
producibly high levels of muscle regeneration [11]. A similar protocol 
was followed for mice used in the transfection, histochemistry and 
cytotoxic T lymphocyte (CTL) assay experiments but samples were 
taken at different time points as detailed below. 
2.3. Histochemistry and immunohistochemistry 
At 1 week post plasmid injection 6 mice in each treatment group 
were killed with an overdose of barbiturate anaesthetic followed by 
cardiac puncture to collect blood. The anterior tibial muscles were 
dissected free from overlying connective tissue. One muscle of each 
pair was frozen in liquid nitrogen as a reserve and the other muscle 
was mounted on a cork block, covered in embedding compound 
(Cryo-M-Bed, Bright, UK) and flash-frozen in isopentane cooled in 
liquid nitrogen. The same procedure was carried out for 6 animals in 
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each treatment group at 6 weeks post plasmid injection. Serial trans-
verse sections were cut at 10 urn in a cryostat from 10 equally spaced 
sites along the length of the muscle, were fixed in paraformaldehyde 
and then stained in a solution of 1 mM X-gal, 5 mM potassium 
ferricyanide, 5 mM potassium ferrocyanide, 2 mM magnesium chlor-
ide in PBS for 1 or 24 h. After washing in PBS, the slides were 
counterstained in alcoholic eosin, dehydrated in ethanol and mounted 
in DPX. Other acetone-fixed slides were stained with a rat monoclonal 
antibody directed against mouse CD4 or CD8 [12], using rabbit anti-
rat immunoglobulin G (IgG) as the secondary antibody and visualised 
with Streptavidin-ABC and DAB followed by counterstaining for ß-
galactosidase. Fibre counts were analysed statistically by two-way 
ANOVA and Student-Newman-Keuls multiple paired comparisons. 
2.4. $-Galactosidase and chloramphenicol acetyltransferase (CAT) 
ELISAs 
For analysis of total ß-galactosidase expression, 7 BALB/c mice 
were pre-treated with barium chloride as above. Five days following 
pretreatment, 25 ug of CMV-ß was injected into the left anterior tibial 
muscle and 25 ug of RSV-ß was injected into the right. In both cases, 
plasmids were coinjected with 25 u,g of RSV-CAT to control for trans-
fection efficiency. Muscles were collected 1 week post plasmid injec-
tion and flash-frozen in liquid nitrogen. 100 ul of lysis buffer (from 
Boehringer ß-galactosidase or CAT ELISA kit) was added with a 
cocktail of protease inhibitors (50 ug/ml antipain, 10 ug/ml aprotinin, 
0.5 Ug/ml leupeptin and 2 ul/ml of a 10 mg/ml stock of PMSF in 
ethanol). The tissue was homogenised with a micropestle and sub-
jected to four freeze/thaw cycles. A further 400 ul of lysis buffer 
with protease inhibitor was added, mixed thoroughly and then spun 
at 13000 rpm for 10 min to pellet all insoluble material. Supernatants 
were stored at —70°C until assayed. For each assay 50 ul of super-
natant was diluted to 200 |il and assayed using the appropriate Boeh-
ringer kit as per the manufacturer's instructions. CAT enzyme levels 
were used to normalise the ß-galactosidase results to compensate for 
variation in transfection efficiency. Transfection data were analysed 
statistically with the Wilcoxon signed rank test. 
2.5. Antibody ELISA 
Microtitre plates (Highbind Multibind flatwell, Grenier, UK) were 
coated with E. coli ß-galactosidase (Sigma) at 10 ug/ml in carbonate 
buffer the day prior to using the plates. Coated plates were blocked 
with a 3% solution of milk powder prior to incubation with serial 
dilutions of mouse serum. A mouse monoclonal anti-ß-galactosidase 
(Sigma G 8021) was used as a positive control. After washing three 
times with PBS (including 0.05% Tween) the secondary antibody, 
rabbit anti-mouse IgG horseradish peroxidase (Biorad), was applied 
for 30 min at 37°C at a dilution of 1:4000 in PBS with 1% FCS. 
Binding of the secondary antibody was visualised with the OPD re-
action developed for 30 min at room temperature and the optical 
density of each well was determined at 492 nm using a plate reader. 
A panel of rabbit polyclonal mouse isotype-specific secondary anti-
bodies (Z0013-Z0016, Dako, UK) were used to identify the IgG iso-
type response in responding animals using the above procedure. Data 
are presented after subtraction of background reading from duplicate 
wells not coated with ß-galactosidase. 
2.6. Cytotoxicity assays 
Animals were treated as detailed in Section 2.2. Spleens were har-
vested at 10 weeks post plasmid injection and cells collected into 
Glutamax/pyruvate DMEM, 50 uM 2ME, 10% fetal calf serum 
(FCS), 1% non-essential amino acids. After a brief period to settle 
clumps, red blood cells were lysed with 5 ml ACK buffer (0.15 M 
NH4CI, 1.0 mM KHCO3, 0.1 mM EDTA at pH 7.2) per spleen for 
5 min at room temperature, cells were washed once in PBS and trypan 
blue-excluded viable cell counts were taken. P815 cells were treated 
with mitomycin C for 20 min at 37°C (50 |!g/ml for 1 X 107 cells/ml), 
washed thoroughly and then pulsed for 1 h at 37°C with 10 uM of the 
ß-galactosidase H-2Ld-restricted cytotoxic epitope peptide (TPHPAR-
IGL [13]). Splenocytes were cocultured at 37°C in 5% CO2 with pep-
tide-pulsed mitomycin C-treated P815 cells at an effector to stimulator 
ratio of 1:1 in the presence of 10 U/ml of human recombinant IL-2 
(Sigma) at an initial cell concentration of 106 cells/ml. Cultures were 
harvested after 5 days and viable cells recovered from Nycoprep gra-
dients (Nycoprep (Animal) 1.077, Nycomed). The CTL assay was 
carried out with 4 h incubation plus or minus 104 P815 target cells 
per well in a 96-well round-bottomed plate with or without the addi-
tion of 10 uM TPHPARIGL peptide. FCS levels were dropped to 5% 
for the assay to reduce background LDH levels. The assay was per-
formed using the Promega Cytox Assay kit as per manufacturer's 
instructions. 
3. Results 
3.1. fi-Galactosidase expression in muscle 
Fig. 1 shows the number of ß-galactosidase-positive fibres 
in mouse anterior tibial muscles at 1 and 6 weeks post plasmid 
injection. No ß-galactosidase-positive fibres were seen in 
muscles injected with the CMV-0 construct. Relatively few 
positive fibres were detected in RSV-ß-injected muscles. This 
number declined between 1 and 6 weeks but the difference is 
not significant. The muscles injected with CMV-ß plasmid 
showed a large number of fibres expressing ß-galactosidase 
at 1 week post injection, but this number had fallen signifi-
cantly to very low levels by 6 weeks post injection (P<0.05). 
Nude animals injected with CMV-ß showed a variable but 
generally high number of ß-galactosidase-positive fibres at 
Fig. 1. The mean number of ß-galactosidase-positive fibres for each plasmid treatment at 1 week (black bars) and 6 weeks (grey bars) post in-
jection. T-bars display the standard error of the mean with n = 6 in the first three groups and n = 5 in the nude group. 
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Fig. 2. A: Mean value for total IgG titre detected at a serum dilu-
tion of 1:100 for each weekly blood sample of animals injected with 
CMV-ß (solid line), RSV-ß (dashed line), CMV-0 (dotted line) and 
nude mice injected with CMV-ß (dot-dash line). Only the first two 
treatments produced titres above baseline. B: Individual animal to-
tal IgG titres detected at a serum dilution of 1:100 for each weekly 
blood sample of animals injected with CMV-ß. Considerable varia-
tion between individuals in evident with one animal showing no re-
sponse. 
1 week post injection and this number did not decline over the 
6 week period of the experiment. The considerable variation 
in number of positive fibres when comparing animals is typ-
ical of such experiments [2,14]. The transfection assay with 
CMV-ß gave a CAT adjusted average of 12.74 ±6.69 S.E. 
(M = 7) compared to 0.798 ±0.067 S.E. (M = 7) for RSV-ß, a 
significant 16-fold difference in levels of expression between 
the two promoters at 1 week post plasmid injection (P = 0.03). 
3.2. Immune responses to ß-galactosidase 
Fig. 2A shows the total IgG response to ß-galactosidase 
over the 6 week period. Not surprisingly, neither the nude 
animals injected with CMV-ß nor the normal animals injected 
with CMV-0 showed any response to ß-galactosidase above 
the normal background. All but one CMV-ß-injected animal 
demonstrated significant antibody titres to ß-galactosidase 
although there was considerable variation between animals 
(Fig. 2B). Animals injected with the RSV-ß plasmid showed 
lower anti-ß-galactosidase antibody levels compared to those 
injected with CMV-ß. Subtyping the IgG response in the nor-
mal animals injected with the CMV-ß plasmid clearly demon-
strates a predominantly IgG2a response (Fig. 3) but those 
animals demonstrating a humoral immune response following 
injection with RSV-ß had a lower IgG2a to IgG2b ratio. IgGx 
titres were as high as those for IgG2b in the CMV-ß injected 
animals and there was also a significant IgG3 titre. In contrast 
the IgGi titre was much lower than the IgG2b and there was 
no detectable IgG3 response in the RSV-ß injected animals. 
The CTL assay demonstrated a strong specific lysis of the 
peptide-pulsed P815 target cells and minimal non-specific lysis 
by splenocytes from CMV-ß treated animals (Fig. 4). In con-
trast splenocytes from CMV-0-treated animals showed low 
but similar lysis of both peptide- and non-peptide-pulsed 
P815 target cells. This result clearly demonstrates a ß-galacto-
sidase-specific CTL response in those animals injected with 
the ß-galactosidase-expressing CMV-ß plasmid. 
3.3. Immunohistochemistry 
Sections from samples taken at 1 week post injection with 
all plasmids showed a heavy mononuclear cell infiltrate con-
taining some CD4-positive cells and few CD8-positive cells. 
By 2 weeks muscles injected with the CMV-ß plasmid show ß-
Fig. 3. The mean IgG titres at a serum dilution of 1:100 for each subclass at 6 weeks post injection for animals showing a humoral immune re-
sponse to ß-galactosidase following injection of RSV-ß (n = 3, black bars) and CMV-ß (n = 5, grey bars). T-bars display the standard error of 
the mean. 
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Fig. 4. The corrected percentage maximum specific lysis generated 
by splenocytes from CMV-ß-treated animals (circles) and CMV-0-
treated animals (squares) at a variety of effector to target ratios. 
Target P815 cells were pulsed with ß-galactosidase-specific peptide 
(solid lines) or left untreated (dashed lines). 
galactosidase-positive fibres apparently under attack by 
mononuclear cells, many of which stain positively for the 
CD8 cell surface marker, indicating they are cytotoxic T-cells 
(Fig. 5). Samples taken at 6 weeks post injection have a min-
imal mononuclear cell infiltrate in the muscle sections. 
4. Discussion 
The continued presence of high numbers of ß-galactosidase-
positive fibres in the nude animals injected with CMV-ß plas-
mid is evidence that this loss of positive fibres is not due to the 
inactivation of the CMV promoter, as previously postulated 
[2,3]. Indeed, the substantial antibody response to ß-galacto-
sidase, the specific in vitro CTL assay and the presence of 
CD8+ mononuclear cells around ß-galactosidase-positive fi-
bres strongly suggests that the loss of ß-galactosidase-positive 
fibres in the RSV-ß- and CMV-ß-injected normal mice is due 
to the action of the immune system. The predominant IgG2a 
response points to activation of the immune system via the 
Thl pathway and this pathway is responsible for the activa-
tion of cytotoxic T lymphocytes [15]. Much of the difference 
in the immune system response to CMV-ß compared to RSV-
ß can be attributed to the level of expression of the ß-galac-
tosidase, as demonstrated by the high number of ß-galactosi-
dase-positive fibres at 1 week following injection of CMV-ß 
( X 8) and the overall higher level of gene expression seen in 
the transfection assay (X16). However, the relative differences 
in isotypes comparing RSV-ß-injected animals to those treated 
with CMV-ß raises the possibility that there may be differ-
ences in the transient expression in non-muscle cells including 
professional antigen presenting cells. The CMV promoter di-
rects ubiquitous expression [16] whereas the RSV promoter 
appears to express particularly well in muscle [17]. Such differ-
ences could help to explain why long-term gene expression has 
been observed in non-nude animals using the RSV promoter 
and a less strongly antigenic reporter gene, luciferase [1]. In-
terestingly, the isotype profiles from these experiments in 
muscle are different from very similar experiments examining 
gene transfer into skin [18]. In the skin studies, the ratio of 
IgG2a to IgGi antibodies was very much higher than in this 
muscle study and may reflect a lack of destruction of the skin 
cells [19], and hence less antigen release, compared to the 
response to gene expression in muscle. Alternatively, skeletal 
muscle may secrete substantial amounts of ß-galactosidase 
compared to skin cells. 
We believe that immune responses to exogenous proteins 
produced in muscle following somatic gene transfer can lead 
to the loss of transfected fibres over time. This fibre loss places 
an important potential limitation on the long-term success of 
gene transfer strategies. Although ß-galactosidase is recog-
nised as a powerful immunogen (e.g. [20-23]), immune system 
responses have been reported to other gene products following 
gene transfer into muscle (e.g. [24-26]) and it seems quite 
probable that in many cases such immune responses may 
lead to a clearance of transfected fibres over time. In the 
studies cited [20-26], viral vectors were used to introduce 
the exogenous gene and the presence of viral proteins from 
the vector, or leakage of viral proteins from the replication-
deficient genome of such vectors, may well have influenced the 
nature of the immune response that was recorded. In contrast, 
the plasmid gene transfer system does not introduce poten-
tially immunogenic proteins at the time of gene transfer and 
Fig. 5. Representative examples of muscle fibres in cross-section from animals injected with the CMV-ß plasmid 2 weeks prior to sampling. 
The sections were immunostained for CD8-positive cells and then histochemically stained for ß-galactosidase expression. Dark brown CD8-pos-
itive cells can be seen attacking the edges of blue-stained muscle fibres that are expressing ß-galactosidase. Images are magnified 1700 times. 
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so results obtained can be specifically attributed to expression 
of the transferred gene. Our observations of the considerable 
loss of transfected fibres suggest the immune system could be 
a serious limitation to gene therapy strategies for diseases of 
muscles, such as Duchenne muscular dystrophy, and may lim-
it the long-term systemic expression of proteins for both sys-
temic treatment and vaccination strategies. 
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